218 related articles for article (PubMed ID: 31960186)
1. TERT promoter hotspot mutations and their relationship with TERT levels and telomere erosion in patients with head and neck squamous cell carcinoma.
Boscolo-Rizzo P; Giunco S; Rampazzo E; Brutti M; Spinato G; Menegaldo A; Stellin M; Mantovani M; Bandolin L; Rossi M; Del Mistro A; Tirelli G; Dei Tos AP; Guerriero A; Niero M; Da Mosto MC; Polesel J; De Rossi A
J Cancer Res Clin Oncol; 2020 Feb; 146(2):381-389. PubMed ID: 31960186
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of promoter mutations in the TERT gene in oral cavity squamous cell carcinoma.
Chang KP; Wang CI; Pickering CR; Huang Y; Tsai CN; Tsang NM; Kao HK; Cheng MH; Myers JN
Head Neck; 2017 Jun; 39(6):1131-1137. PubMed ID: 28230921
[TBL] [Abstract][Full Text] [Related]
3. TERT promoter hot spot mutations are frequent in Indian cervical and oral squamous cell carcinomas.
Vinothkumar V; Arunkumar G; Revathidevi S; Arun K; Manikandan M; Rao AK; Rajkumar KS; Ajay C; Rajaraman R; Ramani R; Murugan AK; Munirajan AK
Tumour Biol; 2016 Jun; 37(6):7907-13. PubMed ID: 26700669
[TBL] [Abstract][Full Text] [Related]
4. hTERT C250T promoter mutation and telomere length as a molecular markers of cancer progression in patients with head and neck cancer.
Barczak W; Suchorska WM; Sobecka A; Bednarowicz K; Machczynski P; Golusinski P; Rubis B; Masternak MM; Golusinski W
Mol Med Rep; 2017 Jul; 16(1):441-446. PubMed ID: 28535013
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological characteristics of TERT promoter mutation and telomere length in hepatocellular carcinoma.
Lee HW; Park TI; Jang SY; Park SY; Park WJ; Jung SJ; Lee JH
Medicine (Baltimore); 2017 Feb; 96(5):e5766. PubMed ID: 28151853
[TBL] [Abstract][Full Text] [Related]
6. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.
Liu T; Wang N; Cao J; Sofiadis A; Dinets A; Zedenius J; Larsson C; Xu D
Oncogene; 2014 Oct; 33(42):4978-84. PubMed ID: 24141777
[TBL] [Abstract][Full Text] [Related]
7. Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer.
Hosen I; Rachakonda PS; Heidenreich B; de Verdier PJ; Ryk C; Steineck G; Hemminki K; Kumar R
Int J Cancer; 2015 Oct; 137(7):1621-9. PubMed ID: 25809917
[TBL] [Abstract][Full Text] [Related]
8. Frequent TERT Promoter Mutations in Ocular Surface Squamous Neoplasia.
Scholz SL; Thomasen H; Reis H; Möller I; Darawsha R; Müller B; Dekowski D; Sucker A; Schilling B; Schadendorf D; Steuhl KP; Paschen A; Westekemper H; Meller D; Griewank KG
Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5854-61. PubMed ID: 26348634
[TBL] [Abstract][Full Text] [Related]
9. Telomerase reverse transcriptase promoter mutations in tumors originating from the adrenal gland and extra-adrenal paraganglia.
Papathomas TG; Oudijk L; Zwarthoff EC; Post E; Duijkers FA; van Noesel MM; Hofland LJ; Pollard PJ; Maher ER; Restuccia DF; Feelders RA; Franssen GJ; Timmers HJ; Sleijfer S; de Herder WW; de Krijger RR; Dinjens WN; Korpershoek E
Endocr Relat Cancer; 2014 Aug; 21(4):653-61. PubMed ID: 24951106
[TBL] [Abstract][Full Text] [Related]
10. Telomere length assessment and molecular characterization of TERT gene promoter in periampullary carcinomas.
Gregório C; Thakur S; Camara Rivero R; Márcia Dos Santos Machado S; Cuenin C; Carreira C; White V; Cree IA; Vukojevic K; Glavina Durdov M; Bersch Osvaldt A; Ashton-Prolla P; Herceg Z; Talukdar FR
Gene; 2023 Jul; 873():147460. PubMed ID: 37150235
[TBL] [Abstract][Full Text] [Related]
11. Telomere shortening in mucosa surrounding the tumor: biosensor of field cancerization and prognostic marker of mucosal failure in head and neck squamous cell carcinoma.
Boscolo-Rizzo P; Rampazzo E; Perissinotto E; Piano MA; Giunco S; Baboci L; Spinato G; Spinato R; Tirelli G; Da Mosto MC; Del Mistro A; De Rossi A
Oral Oncol; 2015 May; 51(5):500-7. PubMed ID: 25771075
[TBL] [Abstract][Full Text] [Related]
12. Telomeres and telomerase in head and neck squamous cell carcinoma: from pathogenesis to clinical implications.
Boscolo-Rizzo P; Da Mosto MC; Rampazzo E; Giunco S; Del Mistro A; Menegaldo A; Baboci L; Mantovani M; Tirelli G; De Rossi A
Cancer Metastasis Rev; 2016 Sep; 35(3):457-74. PubMed ID: 27501725
[TBL] [Abstract][Full Text] [Related]
13. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
[TBL] [Abstract][Full Text] [Related]
14. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.
Wang N; Liu T; Sofiadis A; Juhlin CC; Zedenius J; Höög A; Larsson C; Xu D
Cancer; 2014 Oct; 120(19):2965-79. PubMed ID: 24898513
[TBL] [Abstract][Full Text] [Related]
15. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy.
Wu RC; Ayhan A; Maeda D; Kim KR; Clarke BA; Shaw P; Chui MH; Rosen B; Shih IeM; Wang TL
J Pathol; 2014 Mar; 232(4):473-81. PubMed ID: 24338723
[TBL] [Abstract][Full Text] [Related]
16. TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas.
Gao K; Li G; Qu Y; Wang M; Cui B; Ji M; Shi B; Hou P
Oncotarget; 2016 Feb; 7(8):8712-25. PubMed ID: 26556853
[TBL] [Abstract][Full Text] [Related]
17. TERT promoter mutations in clear cell renal cell carcinoma.
Hosen I; Rachakonda PS; Heidenreich B; Sitaram RT; Ljungberg B; Roos G; Hemminki K; Kumar R
Int J Cancer; 2015 May; 136(10):2448-52. PubMed ID: 25331263
[TBL] [Abstract][Full Text] [Related]
18. Association of Relative Leucocyte Telomere Length and Gene Single Nucleotide Polymorphisms (
Vaiciulis P; Liutkeviciene R; Liutkevicius V; Vilkeviciute A; Gedvilaite G; Uloza V
Cancer Genomics Proteomics; 2020; 17(4):431-439. PubMed ID: 32576588
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity of TERT promoter mutations status in squamous cell carcinomas of different anatomical sites.
Cheng KA; Kurtis B; Babayeva S; Zhuge J; Tantchou I; Cai D; Lafaro RJ; Fallon JT; Zhong M
Ann Diagn Pathol; 2015 Jun; 19(3):146-8. PubMed ID: 25862495
[TBL] [Abstract][Full Text] [Related]
20. Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation.
Huang DS; Wang Z; He XJ; Diplas BH; Yang R; Killela PJ; Meng Q; Ye ZY; Wang W; Jiang XT; Xu L; He XL; Zhao ZS; Xu WJ; Wang HJ; Ma YY; Xia YJ; Li L; Zhang RX; Jin T; Zhao ZK; Xu J; Yu S; Wu F; Liang J; Wang S; Jiao Y; Yan H; Tao HQ
Eur J Cancer; 2015 May; 51(8):969-76. PubMed ID: 25843513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
